SILEXION THERAPEUTICS CORP Net Fee Amt
SILEXION THERAPEUTICS CORP (SLXN) had Net Fee Amt of $1.44 thousand as of 2026-08-07, per its S-1 filed 2026-08-07.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-08-07
- 2026-08-07: Net Fee Amt $1.44K.
- 2026-06-12: Net Fee Amt $415.49.
| Period end | Net Fee Amt |
|---|---|
| 2026-08-07 | $1.44K S-1 · filed 2026-08-07 |
| 2026-06-12 | $415.49 S-3 · filed 2026-06-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |